Using small RNA sequencing, investigators found miRNAs in the blood that track with cirrhosis, hepatitis, type 2 diabetes, or acetaminophen toxicity.
Called the Glyco Liver Profile, the test uses capillary electrophoresis to measure glycosylation of proteins to diagnosis and monitor chronic liver diseases.
The partners will develop biomarkers and assays to evaluate non-alcoholic steatohepatitis, a disease characterized by liver scarring due to inflammation.
Based on genetic patterns in thousands of individuals with primary sclerosing cholangitis, researchers identified four new risk loci and explored ties to IBD.
Pittsburgh-based Curable is building a coalition to sequence genomes of patients with a rare autoimmune disease of the bile ducts to inform drug development.
The CRISPR/Cas9 therapeutics firm could reap billions from the Regeneron collaboration, which includes $75 million up front and a $50 million private placement.
Researchers sequenced and analyzed the negative-sense RNA tilapia lake virus, implicated in large die-offs of farmed and wild tilapia in Israel and Ecuador.
In Nature this week: DNA-free genome editing in plants, new risk loci for atopic dermatitis, and more.
A two-stage genome-wide association study has linked new loci to alcohol-related cirrhosis risk and confirmed a previously identified one.
The company aims to validate two diagnostic algorithms based in part on microRNA biomarkers to identify patients with moderate-to-severe disease.
Using DNA to sketch crime victims might not be a great idea, the NYTimes says.
Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.
Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.
In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.